HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Regulatory Round-Up: RWE Platform Proposed, Brexit Transition Update, EPI Principles Published

Executive Summary

The latest EU regulatory developments - EMA and HMA are looking to build an EU-wide real-world data platform; EU OTC firms can operate as normal in the UK until the end of the year; EMA, HMA and the EC have published key principles on how to develop and use electronic product information for medicines marketed within the EU.  

You may also be interested in...



EU Regulatory News Round Up: NSAIDs During Pregnancy, Estragole Excipients, ePIs

CMDh receives applications to change how NSAIDs are recommended for use during pregnancy; HMPC warns against use of estragole-containing excipients in herbals; EMA adopts new EU common standard for electronic product information on medicines marketed within the region.

Learn From Regulatory Innovation During COVID-19, Urges Global Self-Care Industry

The Global Self-Care Federation has published three papers outlining how regulatory flexibility and innovation seen during the cornavirus pandemic can be brought forward to a post-pandemic consmer heathcare sector. 

Real-World Data One Of Five Areas For Improvement For EU Digital Self-Care Regulation

The AESGP in a new position paper calls for a flexible regulatory framework to unlock the "tremendous opportunity" of digital innovation in self-care. 

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS149822

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel